Recently, sphingosine 1-phosphate (S1P) has been highlighted as an endothelial barrier-stabilizing mediator. FTY720 is a S1P analog originally developed as a novel immunosuppressant. The phosphorylated form of FTY720 binds to S1P receptors to exert S1P-like biological effects, suggesting endothelial barrier promotion by FTY720. To elucidate whether FTY720 induces signaling events related to endothelial barrier enhancement under hyperglycemic conditions, human microvascular endothelial cells (HMVECs) preincubated with hyperglycemic (30 mM) medium were treated with 100 nM FTY720 for 3 h. Immunofluorescent microscopy and coprecipitation study revealed FTY720-induced focal adhesion kinase (FAK)-associated adherens junction (AJ) assembly at cell-cell contacts coincident with formation of a prominent cortical actin ring. FTY720 also induced transmonolayer electrical resistance (TER) augmentation in HMVEC monolayers in both normoglycemic and hyperglycemic conditions, implying endothelial barrier enhancement. Similar to S1P, site-specific FAK tyrosine phosphorylation analysis revealed FTY720-induced FAK [Y 576 ] in hyperglycemic medium to the same pattern observed in normoglycemic medium. FTY720 challenge resulted in small GTPase Rac activation under hyperglycemic conditions, whereas increased Rho activity in hyperglycemic medium was restored to the basal level. Rac protein depletion by small interfering RNA (siRNA) technique completely abolished FTY720-induced FAK [Y 576 ] phosphorylation. These findings strongly suggest the barrier protective effect of FTY720 on HMVEC monolayers in hyperglycemic medium via S1P signaling, further implying the possibility of FTY720 as a therapeutic agent of diabetic vascular disorder. endothelial barrier function; human microvascular endothelial cell; diabetes mellitus; transmonolayer electrical resistance; cytoskeleton AMONG SEVERAL PLATELET-DERIVED lipids, sphingosine 1-phosphate (S1P) is a remarkably effective endothelial cell agonist that induces proliferation, calcium mobilization, adhesion molecule expression, and suppression of apoptosis (2, 8, 11, 12, 17) . Recently, the role of S1P as an endothelial barrierstabilizing mediator has been highlighted (19 -21). Released by stimulated platelets, S1P is present in human serum (26, 27, 36) to bind to the S1P family of receptors (17, 13, 18, 43) . S1P induces barrier enhancement coincident with the formation of a prominent cortical actin ring in pulmonary endothelial monolayers, with a potentially key role for the small GTPase Rac in this process (9, 34). Furthermore, S1P-induced redistribution of focal adhesion proteins [focal adhesion kinase (FAK) and paxillin] to the cell periphery and the site-specific phosphorylation of FAK [Y 576 ] strongly suggest the barrier protective effects of S1P via cytoskeletal rearrangement facilitated by focal adhesion (FA) remodeling (34, 35) .
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FTY720 is a synthetic compound originally developed as a novel immunosuppressant (33, 41) . Chemically modified from Isaria sinclarii (39) , FTY720 activates S1P 1 and S1P 3 receptor subtypes and has a strong structural similarity to sphingosine and S1P (41) . FTY720 is phosphorylated by sphingosine kinase, and the phosphorylated form of FTY720 binds to S1P receptors to exert S1P-like biological effects with varied efficacy and potency (13, 29) . Recently, Peng et al. (26) reported that both S1P and FTY720 reduced pulmonary edema and infiltration of inflammatory cells into the lung in acute lung injury model animals, suggesting the possibility of FTY720 as a therapeutic agent against vascular endothelial disorder. Furthermore, the therapeutic role of FTY720 in a model of chronic mesangioproliferative glomerulonephritis has also been reported (27, 33) . These lines of evidence give rise to the question of whether FTY720 ameliorates diabetic angiopathy, the crucial cause of several diabetic complications, via vascular endothelial barrier enhancement. In the present study, we investigated the role of FTY720 on FA and adherens junction (AJ) remodeling associated with actin redistribution in human microvascular endothelial cells (HMVECs) under both normoglycemic and hyperglycemic conditions. Activity of small GTPases Rac and Rho was also evaluated.
MATERIALS AND METHODS
Cells, reagents, and antibodies. Chemicals and reagents were obtained from Sigma (St. Louis, MO), unless otherwise noted. FTY720 was provided by Novartis Pharma (Basel, Switzerland). Fetal bovine serum (FBS) was obtained from CanSera International (Etobicoke, ON, Canada). Cell culture medium (EBM-2) and growth supplements were obtained from Clonetics (Walkersville, MD). Alexa Fluor 488 anti-mouse IgG antibody, Alexa Fluor 488 anti-rabbit IgG antibody, and Texas red-phalloidin were purchased from Molecular Probes (Eugene, OR Human microvascular endothelial cell culture. HMVECs were obtained from Clonetics and cultured in EBM-2 complete medium containing 20% FBS. Endothelial cell cultures were maintained at 37°C in a humidified atmosphere and grown to contact-inhibited monolayers with typical cobblestone morphology. Cells from each primary flask (passages 4 -10) coated with zeratin (0.025%) were detached with 0.05% trypsin, resuspended in fresh culture medium, and then passaged into gelatinized 6-well plates for Western blot analysis, Rac/Rho activation assay, and coimmunoprecipitation or 12-well plates with gelatinized coverslips for immunofluorescent analysis. Cells grown to 95% confluence on plates were then rendered quiescent in EBM-2 containing 1% FBS for 48 h under both normoglycemic (5.5 mM) and hyperglycemic (30 mM) conditions with or without addition of FTY720 (100 nM final concentration) to the medium for 3 h at the end of 48-h serum deprivation.
Immunofluorescence microscopy. HMVECs prepared on 12-well plates with gelatinized coverslips as described in Human microvascular endothelial cell culture were fixed in 3.7% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min, washed three times with PBS, permeabilized with 0.25% Triton X-100 in 0.1% Tween 20-containing Tris-buffered saline (TBS-T) for 15 min, and blocked with 2% BSA in TBS-T for 30 min. Incubations with primary antibodies of interest were performed in blocking solution (2% BSA in TBS-T) for 1 h at room temperature. After three washes with TBS-T, cells were incubated with appropriate secondary antibodies conjugated to Alexa 488 in blocking solution for 1 h at room temperature. Actin filaments were visualized by staining cells with Texas red-conjugated phalloidin for 1 h at room temperature. After three washes with PBS, the coverslips were mounted with Pristine Mount (Pharma, Tokyo, Japan). Analysis of immunofluorescent staining was performed with a Olympus IX71 microscope with a ϫ40 objective lens (Tokyo, Japan).
RNA interference experiments. For Rac depletion, siGENOME SMARTpoolTM M-003560-06 (Dharmacon, Chicago, IL), a mixture of Rac siRNAs, was used. A nonspecific control siRNA pool was also obtained from Dharmacon.
The nonspecific control siRNA pool was a mixture of four RNA duplexes [5Ј-AUGAACGUGAAUUGCUCAA (sense), 5Ј-UUGAG-CAAUUCACGUUCAU (antisense), 5Ј-UAAGGCUAUGAA-GAGAUAC (sense), 5Ј-GUAUCUCUUCAUAGCCUUA (antisense), 5Ј-AUGUAUUGGCCUGUAUUAG (sense), 5Ј-CUAAUACAGGC- CAAUACAU (antisense), 5Ј-UAGCGACUAAACACAUCAA (sense), 5Ј-UUGAUGUGUUUAGUCGCUA (antisense), respectively] with UU overhangs and a 5Ј-phosphate on the antisense strand. Transfection of Rac siRNA was performed fundamentally according to the manufacturer's protocol. Briefly, HMVECs Ͻ40% confluent on gelatinized six-well plates were incubated with 10% FBS-supplemented medium containing siIMPORTER(X200)/siRNA (200 nM) mixture for 72 h. Cells were then rendered quiescent in EBM-2 containing 0.1% FBS for 24 h before Western blot analysis.
Western blot analysis. After being briefly washed with PBS, cells prepared on six-well dishes as described in Human microvascular endothelial cell culture were lysed with 300 l/well of cell lysis buffer containing 10 mM Tris (pH 7.4), 1% Triton X-100, 0.5% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 0.2 mM EGTA, 0.2 mM vanadate, 0.2 mM PMSF, and 0.5% phosphatase inhibitor cocktail (Sigma). Total cell lysates were cleared by centrifugation, and protein concentration was measured with the DC protein assay kit (Sigma). Lysates were then boiled with the same amount of 3ϫ SDS sample buffer for 5 min, and the same amount of proteins was subjected to 7.5% SDS-PAGE. The separated proteins were transferred to polyvinylidene difluoride (PVDF) membranes by electrotransfer. The blots were subsequently blocked with 5% FBS in TBS-T at room temperature for 1 h and then incubated at 4°C overnight with an primary antibody of interest. After being washed three times for 10 min with TBS-T, the membrane was incubated with 1:1,000 dilution of HRPlinked anti-mouse or -rabbit IgG secondary antibody at room temperature for 1 h. The blots were then visualized with the ECL Western blot detection system. For reprobing analysis, membranes were incubated in reprobing buffer containing 62.5 mM Tris (pH 6.8), 2% deoxycholate, and 100 mM mercaptoethanol at 50°C for 30 min. After being washed four times with TBS-T for 10 min, membranes were incubated with an antibody of interest at room temperature for 1 h and visualized again. The amount of detected proteins was analyzed with Image Quant software.
Immunoprecipitation analysis. After being briefly washed with PBS, HMVECs prepared on six-well dishes as described in Human microvascular endothelial cell culture were lysed with 300 l/well of precipitation buffer containing 50 mM Tris (pH 7.8), 1% Nonidet P-40, 20 mM EDTA, 0.2 mM vanadate, and 0.2 mM PMSF (36) . For immunoprecipitation, 100 l of each cell lysate was diluted with 100 l of the same buffer in a 1.6-ml tube and subsequently incubated with 2.0 g of anti-␤-catenin antibody at 4°C for 1 h, followed by incubation with protein G-Sepharose 4B for 1 h. Sepharose beads were collected by centrifugation (1,500 rpm for 5 min), washed three times with the same buffer, resuspended in 20 l of 3ϫ SDS sample buffer, and then boiled for 5 min. Precipitated proteins were separated as described for Western blot analysis. The resulting membranes were blotted with appropriate antibodies (anti-VE-cadherin antibody or anti-FAK antibody) as described in Western blot analysis. Reprobing analysis of a membrane with an antibody of interest was also performed as described in Western blot analysis. The amount of proteins was analyzed with Image Quant software.
Rac and Rho activation assay. Assessment of Rac GTPase activation was performed with an Rac activation assay kit (Upstate Biotechnology). After being briefly washed with PBS, HMVECs prepared on six-well dishes as described in Human microvascular endothelial cell culture were lysed in 300 l/well pf Mg 2ϩ lysis buffer (MLB) containing 25 mM HEPES, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 10 mM MgCl2, 1 mM EDTA, 2% glycerol, 0.2 mM vanadate, 0.2 mM PMSF, and 1:200 dilution of phosphatase inhibitor cocktail, homogenized by pipetting, and then briefly centrifuged to remove cell debris. The resulting supernatants (200 l) were then incubated with 10 l of agarose-conjugated p21-binding domain of human PAK-1 (residues 67-150) for 30 min. The agarose beads were washed three times with MLB, resuspended in 20 l of 3ϫ SDS sample buffer, and then boiled for 5 min. The samples were then subjected to electrophoresis in 12.5% gels and transferred to PVDF membrane. Precipitated protein was detected by Western blot using mouse monoclonal anti-Rac1 antibody. For total Rac detection, 10 l of the original cell lysates was subjected to electrophoresis in 12.5% gels and recognized by Western blot using anti-Rac1 antibody. To assess Rho GTPase activation, 10 l of agarose-conjugated p21-binding domain of human PAK-1 and anti-Rac1 antibody was substituted with 60 l of glutathione agarose-bound Rhotekin-Rho binding domain protein and anti-Rho antibody, respectively.
Impedance measurements with electric cell-substrate impedance sensing. HMVECs were grown to confluence in polycarbonate wells coated with a double concentration of zeratin (0.05%) containing evaporated gold microelectrodes (surface area 10 Ϫ3 cm 2 ) in series with a large gold counterelectrode (1 cm 2 ) connected to a phase-sensitive lock-in amplifier (16) . Transfection of Rac siRNA was performed in polycarbonate wells fundamentally as described in RNA interference experiments. Measurements of transendothelial electrical resistance (TER) were performed with an electrical cell-substrate impedance sensing system (ECIS) (Applied BioPhysics, Troy, NY) as described previously (9) . Briefly, current was applied across the electrodes by a 4,000-Hz AC voltage source with amplitude of 1 V in series with a resistance of 1 M⍀ to approximate a constant current source (ϳ1 A). The in-phase and out-of-phase voltages between the electrodes were monitored in real time with the lock-in amplifier and subsequently converted to scalar measurements of transendothelial impedance. Values of normalized resistance from each microelectrode were pooled at discrete time points and plotted versus time as means Ϯ SE.
Statistical analysis. Results are expressed as means Ϯ SE of independent experiments. One-way ANOVA followed by post hoc Scheffé's test was performed with StatView software. P Ͻ 0.05 was considered statistically significant.
RESULTS

FTY720 induced redistribution of FAK to cell cortical area.
Effects of hyperglycemic challenge and FTY720 treatment on the distribution of FAK were monitored by immunofluorescent microscopy. In quiescent HMVECs, FAK stains diffusely in the cytoplasm as well as at sites of stress fiber attachment to the randomly arranged FA (Fig. 1, A-C) . Incubation of HMVEC Fig. 4 . Effects of FTY720 on interaction between ␤-catenin and VE-cadherin. A: HMVECs were lysed as described in MATERIALS AND METHODS. ␤-Catenin was then immunoprecipitated (IP), and resulting membranes were blotted with anti-VE-cadherin antibody. Reprobing analysis with anti-␤-catenin antibody was subsequently performed. Representative blots of 6 independent experiments are shown. B: amounts of VE-cadherin coprecipitated with ␤-catenin were quantified and analyzed statistically. Values indicate the amount (%) of VE-cadherin assuming the control value as 100% (mean Ϯ SE). Treatment groups are as described in Fig. 1 . C: ␤-catenin was then immunoprecipitated, and resulting membranes were blotted with anti-FAK antibody. Reprobing analysis with anti-␤-catenin antibody was subsequently performed. Representative blots of 6 independent experiments are shown. D: amounts of FAK coprecipitated with ␤-catenin were quantified and analyzed statistically. Values indicate the amount (%) of FAK assuming the control value as 100% (means Ϯ SE). Treatment groups are as described in Fig. 1 . monolayers with 100 nM FTY720 for 3 h resulted in a redistribution of FAK to the cell periphery associated with the enhancement of cortical actin staining (Fig. 1, D-F) . Hyperglycemic challenge (30 mM for 48 h) induced minute and random stress fiber formation associated with redistribution of FAK to sites of stress fiber attachment (Fig. 1, G-I (Fig. 1, J-L) .
FTY720 induced redistribution of ␣-catenin, ␤-catenin, and VE-cadherin. FTY720-induced redistribution of ␣-catenin, ␤-catenin, and VE-cadherin was also monitored by immunofluorescent microscopy. FTY720 (100 nM) challenge for 3 h induced the enhancement of immunofluorescent staining for AJ proteins (␣-catenin, ␤-catenin, and VE-cadherin) at the cellcell contact area coincident with cortical actin enhancement (Fig. 2, A-C, d-f ). Hyperglycemic challenge (30 mM for 48 h) resulted in reduced distribution of AJ proteins at the cell-cell contact area coincident with minute and random stress fiber formation (Fig. 2, A-C, g-i) . Treatment of cells with 100 nM FTY720 for 3 h in hyperglycemic (30 mM) medium after the 30 mM glucose challenge for 45 h augmented the distribution of AJ proteins at cell-cell contacts associated with cortical actin enhancement (Fig. 2, A-C, j-l) .
FTY720 enhances endothelial cell barrier functions. Next, to investigate the effect of FTY720 on endothelial barrier properties in HMVEC monolayers under both normo-and hyperglycemic conditions, HMVECs on gold microelectrodes were challenged with FTY720 (100 nM) and the change in TER was monitored (Fig. 3) . FTY720 augmented sustained increase in TER from 10 min after FTY720 addition under both normoand hyperglycemic conditions (Fig. 3) . In both normoglycemic and hyperglycemic media, Rac protein depletion by siRNA technique resulted in incomplete but evidently significant suppression of TER enhancement by FTY720 (Fig. 3) , whereas the control siRNA did not inhibit FTY720-induced TER augmentation (Fig. 3) . In both normoglycemic and hyperglycemic media, P values indicating statistical significance of the difference in FTY720-induced TER changes between Rac siRNAtransfected and nontransfected cells were below 0.05 from 40 min after the beginning of FTY720 challenge. The efficacy of Rac siRNA is shown in Fig. 7 .
Interaction of ␤-catenin with VE-cadherin and FAK. To investigate the possible effect of FTY720 on AJ remodeling, ␤-catenin was immunoprecipitated and amounts of coprecipitated VE-cadherin and FAK were evaluated as described in MATERIALS AND METHODS. Stimulation of HMVECs with 100 nM FTY720 for 3 h resulted in an increased amount of VEcadherin coprecipitated with ␤-catenin under both normoglycemic and hyperglycemic conditions (Fig. 4, A and B) . Incubation of HMVECs with 30 mM hyperglycemic medium for 48 h failed to induce remarkable change in ␤-catenin-VEcadherin interaction (Fig. 4, A and B) . Similar to the interplay between ␤-catenin and VE-cadherin, 3-h incubation of HMVECs with FTY720 (100 nM) augmented VE-cadherin association with FAK under both normoglycemic and hyperglycemic conditions (Fig. 4, C and D) .
FTY720 induced site-specific FAK tyrosine phosphorylation. FTY720 (100 nM) induced significant FAK [Y 576 ] phosphorylation in the normoglycemic medium within 3 h (Fig. 5B) . In FTY720 induced Rac activation. FTY720 (100 nM) challenge for 3 h resulted in Rac activation under normoglycemic conditions (Fig. 6) . Incubation of HMVECs with 30 mM hyperglycemic medium for 48 h did not induce significant change in small GTPase Rac activity (Fig. 6) . Rac activation was also induced by 3-h FTY720 (100 nM) challenge in hyperglycemic (30 mM) medium preceded by incubation with 30 mM hyperglycemic medium for 45 h (Fig. 6) .
FTY720 did not induce Rho activation. FTY720 (100 nM) challenge for 3 h did not induce Rho activation under normoglycemic conditions (Fig. 6) . Incubation of HMVECs with 30 mM hyperglycemic medium resulted in significant increase in small GTPase Rho activity that was restored to basal level after FTY720 (100 nM) challenge for 3 h in the same 30 mM hyperglycemic medium (Fig. 6) .
FTY720-induced FAK tyrosine phosphorylation was diminished by Rac protein depletion.
HMVECs transfected with Rac siRNA were incubated with normoglycemic medium and subsequently stimulated with FTY720 (100 nM) for 3 h. Total cell lysates were then subjected to electrophoresis and blotted with anti-FAK [Y 576 ] phosphospecific antibody as described in MATERIALS AND METHODS. FTY720 failed to induce FAK [Y 576 ] phosphorylation in Rac-depleted HMVECs within 3 h (Fig. 7A) . Rac depletion also inhibited FTY720-induced FAK [Y 576 ] phosphorylation in 30 mM hyperglycemic medium (Fig. 7B ).
DISCUSSION
The primary pathway involved in endothelial barrier permeability under pathological conditions is paracellular transport of fluid and macromolecules through intercellular gaps that form after the disruption of intercellular AJ and FA complexes (19) . An increase in vascular permeability is a fundamental feature of inflammation and can lead to proliferative diabetic retinopathy and mesangial matrix expansion in the kidney (28, 30, 40) . Impaired vascular endothelial integrity contributes to the pathogenesis of diabetes-associated atherosclerosis by facilitating the deposition of lipid molecules in the vessel wall and accelerating the development of inflammation (4). Considering the pivotal role of increased endothelial permeability in the progression of diabetic complications, efficient augmentation of endothelial barrier function is essential in the therapy of diabetic patients.
AJ proteins are active participants in the modulation of vascular permeability (21, 46) . As a primary component of AJ, VE-cadherin connects adjacent endothelial cells via homophilic binding of the extracellular domain (46) . The intracellular domain of VE-cadherin interacts with actin cytoskeleton through the catenins (5, 46) . Several hyperpermeability factors induce tyrosine phosphorylation of ␤-catenin, leading to disassembly of AJ associated with intracellular gap forma- Fig. 6 . Effects of FTY720 on Rac and Rho activity. A: HMVECs were prepared, stimulated, and lysed as described in MATERIALS AND METHODS. Activated GTP-bound Rac was then immunoprecipitated and blotted. Total Rac contents were detected with total cell lysates. Representative blots of 6 independent experiments are shown. B: amounts of precipitated GTP-bound Rac were quantified and analyzed statistically. Values indicate the amount (%) of GTP-bound Rac assuming the control value as 100% (means Ϯ SE). C: activated GTP-bound Rho was then immunoprecipitated and blotted. Total Rho contents were detected with total cell lysates. Representative blots of 6 independent experiments are shown. D: amounts of precipitated GTP-bound Rho were quantified and analyzed statistically. Values indicate the amount (%) of GTP-bound Rho assuming the control value as 100% (means Ϯ SE). Treatment groups are as described in Fig. 1. tion (1, 6) . FA is also involved in the regulation of vascular permeability. The attachment of endothelial cells to extracellular matrix (ECM) is mediated by FA, which links to the cytoskeleton. Cell-ECM interaction is dynamically controlled through assembly and disassembly by FAs (10, 31) . Blocking the integrin-ECM attachment increases vascular endothelial permeability (3, 44) , and several lines of evidence suggest the participation of FA remodeling in the endothelial contractile reaction and permeability response (46) .
FAK plays a pivotal role in FA remodeling associated with the regulation of endothelial permeability. Recently, we reported (34) striking differences in the tyrosine phosphorylation profiles between S1P and thrombin treatments in human pulmonary arterial endothelial cells. S1P induced FAK phosphorylation at [Y 576 ] via Src signaling pathway, whereas the phosphorylation status of [Y 397 ] and [Y 925 ] were not influenced by S1P challenge (34) . Conversely, thrombin, the strong hyperpermeability factor, induced significant phosphorylation of FAK at tyrosine residues [Y 397 ], [Y 576 ], and [Y 925 ] through the mediation of multiple signaling pathways (35) . Furthermore, S1P (0.5 M) induced a dramatic redistribution of FAK to a cell periphery consistent with the enhancement of the cortical actin ring, whereas thrombin (100 nM) stimulation resulted in the formation of massive stress fibers and intercellular gaps coincident with the redistribution of FAK to the ends of stress fibers (34, 35) . In the case of endothelial barrier property regulation by mechanical stresses, shear stress within 15 min augmented TER associated with the redistribution of FAK to a cell periphery, the enhancement of the cortical actin ring, and FAK [Y 576 ] phosphorylation (37) . These findings suggest common signal transduction pathways involved in endothelial barrier regulation facilitated by FAK.
The roles of small GTPases Rho and Rac in endothelial barrier regulation are also intriguing. Rac controls cadherinmediated cell-cell adhesion and formation of AJ complexes via modulation of cadherin-catenin interaction (14) . In contrast, activation of RhoA is associated with AJ disassembly (16, 21) and FA formation associated with actin filament polymerization (22, 46) . Furthermore, FAK may regulate Rac activity by activating G protein-coupled receptor kinase interactor-1 (GIT1), which complexes with Rac1-specific GEF (25) . Knockdown of GIT1 leads to an additional increase in endothelial permeability in response to thrombin (42) . We also reported (34) the redistribution of both GIT1 and FAK induced by S1P to the cell periphery and the transient association of GIT1 with paxillin, a member of the FA proteins. This emerging evidence suggests the important role of FAK-GIT-Rac signaling in endothelial barrier enhancement.
In the present study, we investigated the role of FTY720, a S1P analog, on FA and AJ remodeling in HMVECs under both normoglycemic and hyperglycemic conditions. FTY720 is phosphorylated by sphingosine kinase in vascular endothelial cells to bind with S1P receptors (29) . We chose 3 h as the FTY720 incubation time period because 3 h is sufficient for FTY720 to be phosphorylated by sphingosine kinases (29) . We also chose 100 nM as the FTY720 concentration considering the affinity of phosphorylated FTY720 with S1P receptors and the effect of FTY720 on cell migration reported previously (15, 29) .
Incubation of HMVEC monolayers with 100 nM FTY720 for 3 h resulted in a redistribution of FAK to the cell periphery associated with the enhancement of cortical actin staining (Fig.  1, D-F) . Hyperglycemic challenge (30 mM for 48 h) induced minute and random stress fiber formation associated with redistribution of FAK to sites of stress fiber attachment (Fig. 1,  G-I ). Treatment of cells with 100 nM FTY720 for 3 h under hyperglycemic conditions (30 mM) preceded by hyperglycemic challenge for 45 h mimicked the cell peripheral redistribution of FAK associated with cortical actin enhancement as observed under normoglycemic conditions (Fig. 1, J-L) . Considering the S1P-induced FAK redistribution to the cell periphery (34, 35) , these present findings suggest a similar effect of FTY720 with S1P on FAK distribution associated with actin cytoskeletal rearrangement in HMVECs under hyperglycemic conditions. FTY720 challenge also enhanced the immunofluorescent staining for AJ proteins (␣-catenin, ␤-catenin, and VE-cadherin) at the cell-cell contact area under both normoglycemic and hyperglycemic conditions (Fig. 2) , suggesting AJ assembly induced by FTY720.
We also monitored TER by ECIS to investigate the effect of FTY720 on endothelial integrity. ECIS experiments revealed FTY720-induced TER augmentation in HMVEC monolayers under both normoglycemic and hyperglycemic conditions (Fig.  3) . Furthermore, Rac protein depletion by Rac siRNA resulted in significant decrease in FTY720-induced endothelial barrier enhancement (Fig. 3) . These results strongly imply FTY720-induced TER augmentation at least partly via Rac signaling pathway and the possibility of FTY720 as a candidate therapeutic agent against vascular disorder in diabetes. In addition, a coimmunoprecipitation study revealed interaction of ␤-catenin with VE-cadherin (Fig. 4, A and B) and FAK (Fig. 4, C and D) enhanced by FTY720 in both normoglycemic and hyperglycemic media. Despite the unsatisfactory data for TER in hyperglycemic media, these findings strongly suggest FTY720-induced endothelial barrier restoration via AJ assembly and the possible involvement of FAK in this process in conjunction with morphological findings shown in Fig. 1 (Fig. 5) . This phosphorylation profile is the same as we reported previously in S1P-stimulated human pulmonary arterial endothelial cells (35) , suggesting the similarity between FTY720 and S1P signaling (1 (Figs. 1 and 2) . Furthermore, FTY720 challenge under hyperglycemic conditions induced FAK phosphorylation of the same profile as observed under normoglycemic conditions (Fig. 5) . Recently, we reported (34, 35, 37) differential FAK tyrosine phosphorylation profiles induced by S1P, thrombin, and mechanical stresses. Furthermore, assessment of TER revealed S1P-induced restoration of the endothelial barrier integrity disrupted by thrombin (9) . Briefly, FTY720 conditioned FAK tyrosine phosphorylation status to the same profile induced by S1P (Fig. 5) , suggesting endothelial barrier amelioration by FTY720 in the hyperglycemic medium with a potentially key role of FAK.
Effects of FTY720 on Rac and Rho were also further investigated. FTY720 challenge for 3 h resulted in Rac activation under both normoglycemic and hyperglycemic conditions (Fig. 6, A and B) . Intriguingly, incubation of HMVECs with hyperglycemic medium resulted in significant increase in small GTPase Rho activity that was restored to basal level by FTY720 (Fig. 6, C and D) . Furthermore, FTY720-induced FAK [Y 576 ] phosphorylation was completely abolished by Rac protein depletion by siRNA technique, suggesting the pivotal role of Rac in FTY720-mediated endothelial barrier enhancement after both normoglycemic and hyperglycemic preincubation (Fig. 7) . Together with the results obtained in the ECIS experiments (Fig. 3) , these findings strongly suggest the role of FTY720 in Rac/Rho-mediated barrier regulation. Among several results achieved in the present study, FTY720-induced inhibition of elevated Rho activity by hyperglycemic challenge might play the key role in vascular barrier protection by FTY720. FTY720 also induced Rac activation in hyperglycemic medium, suggesting the synergistic role of Rac and Rho in the maintenance of vascular barrier integrity.
In summary, we have demonstrated FTY720-induced redistribution of FAK, augmentation of TER, site-specific FAK tyrosine phosphorylation, AJ assembly, and regulation of Rho/ Rac activity in HMVECs under hyperglycemic conditions. These results strongly suggest the pivotal role of FTY720 to ameliorate endothelial barrier function disturbed by hyperglycemic challenge. Recently, the potent S1P receptor-independent mechanisms in endothelial cell barrier enhancement by FTY720 have emerged (7). FTY720-induced significantly slower increase in endothelial resistance and extremely long duration of TER enhancement were also observed in our experiments (Fig. 3) . These findings might be attributed to the delayed activation of FTY720 by sphingosine kinase (13, 29) and the difference in affinity to S1P receptors, respectively. In the present study, Rac protein depletion resulted in significant inhibition of FTY720-induced TER augmentation. Considering accumulating evidence for S1P receptor-mediated Rac activation (13, 42) , the endothelial barrier protective effect of FTY720 might at least partly be via S1P receptor activation.
Although the precise mechanisms of endothelial barrier protection by FTY720 via S1P receptor signaling remain to be elucidated (38) , results of the present study indicate the possibility of FTY720 as a therapeutic agent of diabetic microangiopathy related to vascular endothelial disorder. To elucidate the effects of FTY720 on diabetic complication, several experiments targeting diabetic nephropathy in diabetic model rats are in progress. FTY720 might be effective on histopathological changes in the kidney of diabetic rats. Urinary protein excretion might also be diminished by FTY720 (data not shown). Future work will be performed with in vivo models to elucidate the precise mechanisms of FTY720 signaling and the possibility of FTY720 as a therapeutic agent for diabetic vascular complications.
